Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 cohorts, as outlined below. The initial 3 subjects will be sequentially enrolled in a staggered fashion, with a 7 day interval between each subject to enable the capture and monitoring of any acute and subacute toxicities.

Trial Details

NCT ID
NCT05618925
Phase
PHASE1
Sponsor
ImmunityBio, Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • N803
  • CD19t-haNK suspension
  • Cyclophosphamide
  • Fludarabine
  • Rituximab
Locations (sample)
  • Newport Beach, California, United States|33.61891,-117.92895
  • Tyler, Texas, United States|32.35126,-95.30106

Key Eligibility Criteria

  • Age ≥ 18 years old.
  • Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committe…
  • Histologically documented CD19- and CD20-positive B-cell NHL with the following specific criteria:
  • Have active disease after ≥ 2 lines of cytotoxic chemotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →